Quantcast
Channel: Australia Headlines on One News Page [United States]
Viewing all 53225 articles
Browse latest View live

Zealand Pharma 2017 full-year results in line with guidance - considerable progress in the clinical portfolio

March 7, 2018, 6:13 am
$
0
0
* Company announcement - No. 8 / 2018*

**Zealand Pharma 2017 full-year results in line with guidance - considerable progress in the clinical portfolio **

Copenhagen, March 7, 2018 - Zealand Pharma A/S ("Zealand") (CVR No. 20 04 50 78) announces financial results in line with guidance and considerable progress for its product portfolio and business for the 12-month period from January 1 to December 31, 2017.

*Financial results for the full year 2017*

o    Revenue of DKK 139.8 million/USD 22.5 million (-40% vs. 2016).

·            Royalty revenue of DKK 38.8 million/USD 6.2 million (+59% vs. 2016).

·            Milestone revenue of DKK 101.0 million/USD 16.3 million (-52% vs. 2016).

o    Net operating expenses of DKK 371.5 million/USD 59.9 million (+16% vs. 2016).

o    Net loss for the year of DKK 272.3 million/USD 43.9 million (+77% vs. 2016).

o   Cash including securities amounted to DKK 669.7 million/USD 107.9 million at year-end (2016: DKK 642.1 million/USD 91.0 million).

*Business highlights and updates for Q4 2017 and the period thereafter*

o    Glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome: 

·            Orphan drug designation granted by the FDA.

·            Phase 2 results presented at ASPEN conference in Las Vegas.

·            PK trial concluded, confirming potential for once-weekly dosing.

·            Principal investigators for Phase 3 program appointed.

o    Dasiglucagon HypoPal^® rescue pen: First Phase 3 trial completed and second Phase 3 trial ongoing with results expected in 2018.

o    Dasiglucagon for the treatment of congenital hyperinsulinism: Safe-to-proceed letter from the FDA, confirming readiness for Phase 3 initiation.

o    Dasiglucagon for the treatment of diabetes in dual-hormone pump: Phase 2a data presented at ATTD conference in Vienna.

o    Research collaborations with Uniquest (Australia) and Torrey Pines (U.S.) to identify peptides relevant to specialty gastrointestinal and metabolic diseases.

o    Strengthening of organizational capabilities and Ivan Møller appointed as Senior Vice President, Technical Development & Operations.

o    Zealand has retained Dr. Francois Nader, MD, MBA as strategic adviser to Management to leverage his deep U.S. and global biopharma expertise,

*Britt Meelby Jensen, President and CEO of Zealand**, comments on the year: *

"2017 was a defining year for Zealand, with significant progress across the business. Our portfolio includes four late stage clinical programs where we have full ownership, one in Phase 3 and two planned for Phase 3 initiation this year, with potential to launch into major markets in three to four years. With expanded market access for Soliqua^® 100/33 in the U.S., we expect substantial increases in royalty revenue from Sanofi in the years to come. I look forward to strong progress for our late-stage clinical programs during 2018, to the benefit of both patients and shareholders."

*Conference call today at 4:00 pm CET / 10:00 am ET*

 Zealand's Management will be hosting a conference call today at 16:00 CET to present the full-year results and the Annual Report for 2017. Participating in the call will be President and Chief Executive Officer Britt Meelby Jensen, Executive Vice President and Chief Financial Officer Mats Blom and EVP Chief Medical & Development Officer Adam Steensberg. The presentation will be followed by a Q&A session.

The conference call will be conducted in English, and the dial-in numbers are:
DK standard access             +45 3515 8121
U.K. and international          +44 (0) 330 336 9411
U.S. (free dial-in)                 +1 646 828 8143
Passcode                            9815289

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/9415ce91-6008-470e-9645-d5976b04ad26

http://www.globenewswire.com/NewsRoom/AttachmentNg/bd4f096a-1062-49ca-99ce-9b6fb8923128 Reported by GlobeNewswire 2 hours ago.
↧
Search
↧

A love note to science: Oldest known message in a bottle found in Australia

March 7, 2018, 6:33 am
$
0
0
A couple has recovered the oldest-known message in a bottle from a beach on Australia’s west coast, some 130 years after a German sailor threw it into the Indian Ocean. Reported by CTV News 2 hours ago.
↧

Oldest message in a bottle found in Australia

March 7, 2018, 8:22 am
$
0
0
A gin bottle found on an Australian beach contains a 132-year-old message, one of hundreds of bottles tossed into the ocean p -More-  Reported by SmartBrief 12 minutes ago.
↧

Sport24.co.za | Proteas hopeful of Bavuma fitness

March 7, 2018, 7:45 am
$
0
0
Proteas coach Ottis Gibson is hopeful that middle order batsman Temba Bavuma will be fit for the second Test against Australia in Port Elizabeth. Reported by News24 49 minutes ago.
↧

Kimba Journal: A Farming Town Divided: Do We Want a Nuclear Site that Brings Jobs?

March 7, 2018, 6:49 am
$
0
0
Wheat farming has been the economic mainstay of Kimba, South Australia. Now, the town is bitterly split over a plan to host a medical nuclear waste site. Reported by NYTimes.com 2 hours ago.
↧
↧

Kojamo plc: Kojamo closes EUR 500 million notes issue

March 7, 2018, 7:05 am
$
0
0
KOJAMO PLC, STOCK EXCHANGE RELEASE 7 March 2018 at 5:00 p.m.

 *NOT FOR PUBLISHING OR DISTRIBUTION, WHETHER IN WHOLE OR IN PART, EITHER DIRECTLY OR INDIRECTLY IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER COUNTRIES WHERE PUBLICATION OR DISTRIBUTION WOULD BE AGAINST THE LAW*

Kojamo plc has today issued EUR 500 million senior unsecured notes (the "*Notes*"). The maturity of the euro-denominated Notes is 7 years, and the maturity date is 7 March 2025. The Notes carry a fixed annual coupon of 1.625 per cent, payable annually on 7 March. 

The Irish Stock Exchange has on 5 March 2018 approved the listing prospectus of the Notes, which is available in English on the company's website at www.kojamo.fi/en/investors. The Notes have been admitted to the official list of the Irish Stock Exchange and to trade on its regulated market. 

The company will use the proceeds of the issuance of the Notes to repay one or more secured loan facilities in the approximate amount of EUR 300 million, for general corporate purposes and for supporting the growth targets of the company. 

Danske Bank A/S, Deutsche Bank AG, London Branch, Nordea Bank AB (publ), and Svenska Handelsbanken AB (publ) acted as Joint Bookrunners in the issuance. 

Helsinki, 7 March 2018 

KOJAMO PLC 

Further information:
Jani Nieminen, CEO, tel. +358 20 508 3201
Erik Hjelt, CFO, tel. +358 20 508 3225

Kojamo is the front-runner in rental housing and real estate investments. It has undergone major renewals in recent years. The renewed Kojamo is able to provide better urban housing in a rapidly changing world. Kojamo is transforming Finnish society together with its customers, other companies and operators, as well as cities.* *

*Disclaimer* 

This release is for information purposes only and is not to be construed as an offer to purchase or sell or a solicitation of an offer to purchase or sell with respect to any securities of Kojamo plc ("*Kojamo*"). The distribution of this release and the related material concerning the issuance of EUR 500 million notes (the "*Notes*") may, in certain jurisdictions, be restricted by law. No actions have been taken to register or qualify the Notes, or otherwise to permit a public offering of the Notes, in any jurisdiction. Any offering material or documentation related to the Notes may be received only in compliance with applicable exemptions or restrictions. Persons into whose possession this release or any such offering material or documentation may come are required to inform themselves of and observe all such restrictions. This release and any such offering material or documentation may not be distributed or published in any country or jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction or would require actions under the laws of a state or jurisdiction. In particular this release and any such offering material or documentation may not be distributed in the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or any other jurisdiction in which it would not be permissible to offer the Notes and this release and any related material concerning the issuance of the Notes may not be sent to any person in the beforementioned jurisdictions. The information contained herein shall not constitute an offer to sell or buy, or a solicitation of an offer to buy or sell any of Kojamo's securities including the Notes to any person in any jurisdiction in which such offer, solicitation or sale would be unlawful. Neither Kojamo, the joint bookrunners, nor their representatives accept any legal responsibility for any violation by any person, whether or not the persons contemplating investing in or divesting Kojamo's securities including the Notes are aware of such restrictions. The Notes have not been and will not be registered under the U.S. Securities Act, or under the securities laws of any state or other jurisdiction of the United States. The Notes may not be offered, sold, pledged or otherwise transferred directly or indirectly within the United States or to, or for the account or benefit of, U.S. Persons.

This announcement is not directed at retail clients (as defined in the Product Intervention (Contingent Convertible Instruments and Mutual Society Shares) Instrument 2015 of the Financial Conduct Authority of the United Kingdom) in the European Economic Area ("*EEA*"). The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the EEA. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, "*MiFID II*"); or (ii) a customer within the meaning of Directive 2002/92/EC, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II. Consequently no key information document required by Regulation (EU) No 1286/2014 (the "*PRIIPs Regulation*") for offering or selling the Notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation.

Solely for the purposes of each manufacturer's product approval process, the target market assessment in respect of the Notes has led to the conclusion that: (i) the target market for the Notes is eligible counterparties and professional clients only, each as defined in MiFID II; and (ii) all channels for distribution of the Notes to eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the Notes (a "*distributor*") should take into consideration the manufacturers' target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the Notes (by either adopting or refining the manufacturers' target market assessment) and determining appropriate distribution channels.

The information provided in this release and any offer materials relating to the Notes are addressed to and directed only at persons in the United Kingdom in circumstances where Section 21(1) of the Financial Services and Markets Act 2000 as amended, does not apply and are solely directed at persons in the United Kingdom who (a) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "*Order*") or (b) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Order, or (c) other persons to whom they may be lawfully communicated (all such persons together being referred to as "*relevant persons*"). This release is directed only at relevant persons and any person who is not a relevant person must not act or rely on this document or any of its contents. Reported by GlobeNewswire 1 hour ago.
↧

Perth woman gives birth 15 minutes after finding out she's pregnant

March 7, 2018, 7:09 am
$
0
0
Perth woman gives birth 15 minutes after finding out she's pregnant When property manager Jayde Lawrence, 27, from Perth, Western Australia, was given an emergency ultrasound after going to hospital with unexplained stomach pains, nurses found a heartbeat. Reported by MailOnline 1 hour ago.
↧

Madeline Cowe flaunts slender figure at Marc Jacobs Beauty event

March 7, 2018, 8:29 am
$
0
0
Madeline Cowe flaunts slender figure at Marc Jacobs Beauty event She's the former Miss World Australia who also tried her luck on Australia's Next Top Model. Reported by MailOnline 6 minutes ago.
↧
Search

Bone Therapeutics Successfully Raises EUR 19.45 Million of Commitments in Convertible Bond Placement

March 7, 2018, 7:17 am
$
0
0
*Regulated Information - Inside Information - 7 March 2018 - 4 pm CET*

*NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO*

*Bone Therapeutics Successfully Raises EUR 19.45 Million of Commitments in Convertible Bond Placement*

*Gosselies, Belgium, 7 March 2018, 4 pm CET - Bone Therapeutics* (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases (the "Company"), today announces that it has successfully placed senior, unsecured Convertible Bonds (the "CBs") with a total commitment of EUR 19.45 million via a private placement.

*Thomas Lienard, Chief Executive Officer of Bone Therapeutics, commented:* "I am very pleased to announce this successful placing today which will support us in the development of our unique pipeline of cell therapy products. We are delighted by the level of interest and support we have received from international and local investors, further validating the potential of our novel cell therapy platform. Following the positive interim data from our trials with our allogeneic product ALLOB^® for delayed union fractures and spinal fusion, we are increasingly confident about the potential of our products to address these large markets and make a real difference to the lives of patients. We will continue to fully focus on delivering on our clinical development strategy and look forward to further value inflection points later in 2018."

Bone Therapeutics intends to use the net proceeds of the Offering for:

· Finalising the Phase I/IIA delayed-union trial (ALLOB^®) and beginning recruitment of the next phase (approx. 20% of the net proceeds);
· Finalising the Phase IIA lumbar spinal fusion trial (ALLOB^®) and initiating the groundwork for the next phase (in vivo, EU & US clinical and regulatory preparation) (approx. 20% of the net proceeds);
· Further patient enrolment of the Phase III osteonecrosis trial (PREOB^®) with completion of the interim analysis and continued follow-up (approx. 20% of the net proceeds);
· Optimization and scale-up for the allogeneic product (approx. 20% of the net proceeds); and
· Other and general corporate expenses

As a result of the successful completion of the Offering, the Company expects to have sufficient cash to meet its present requirements and to carry out its strategic objectives and cover its working capital needs for a period until the end of Q3 2019.

The CBs will be in registered form, denominated EUR 2,500 each. The CBs will not bear any coupon and have a maturity date of twelve months after issuance. The CBs are convertible to ordinary shares at CB holders' convenience before maturity or are automatically converted at maturity date at the Conversion Price. The Conversion Price will be equal to 92% of the Volume-Weighted-Averaged-Price of the Company's shares as provided by Bloomberg LP of the day immediately preceding CB holder's request of conversion or maturity date, but not lower than the par value (EUR 2.14) of the Company's share. Upon conversion of the CBs, the new shares issued shall immediately bear the same right of all other existing shares and could be traded on the Euronext stock exchanges in Brussels and in Paris. The Company has the right to redeem the CB at a price of EUR 2,577.31 instead of issuing new shares.

Each subscribed CB is accompanied by 19 bond warrants (the "Bond Warrants") in registered form with a warrant term of 19 months. Each Bond Warrant entitles its holder to subscribe to one CB and can be exercised at an exercise price of EUR 2,500 per CB at the request of the warrant holder at any time during the warrant term. The warrant holders are obliged to exercise at least one of the 19 Bond Warrants each 30 calendar days.

A total amount of EUR 19.45 million in committed capital has been subscribed during the Offering. Part of the investors have decided to immediately exercise warrants resulting in an immediate gross proceed of about EUR 6.58 million and 565,773 new shares to be created, increasing the total outstanding shares from 6,849,654 to 7,415,427 ordinary shares. The remaining warrants will be exercised providing an additional proceed of EUR 12.87 million over a maximum period of 19 months.

The Convertible Bonds were offered through an accelerated bookbuilding offering, open to institutional investors and such other investors as permitted under applicable private placement exceptions only. Bryan, Garnier & Co. acted as Sole Bookrunner for the Offering.

*About Bone Therapeutics*

Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics' technology is based on a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells into "osteoblastic", or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.

The Company's primary clinical focus is ALLOB^®, an allogeneic "off-the-shelf" cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB^®, obtained from patient's own bone marrow and currently in Phase III development for osteonecrosis of the hip.

Bone Therapeutics' cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com.

*Contacts*

*Bone Therapeutics SA*
Thomas Lienard, Chief Executive Officer
Jean-Luc Vandebroek, Chief Financial Officer
Tel: +32 (0)2 529 59 90
investorrelations@bonetherapeutics.com

For Belgium and International Media Enquiries:
*Consilium Strategic Communications*
Amber Fennell, Jessica Hodgson, Hendrik Thys and Lindsey Neville
Tel: +44 (0) 20 3709 5701
bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries:
*NewCap Investor Relations & Financial Communications*
Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau
Tel: + 33 (0)1 44 71 94 94
bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

No communication and no information in respect of the Offering may be distributed to the public in any jurisdiction where a registration or approval is required. No steps have been or will be taken in any jurisdiction where such steps would be required. The Offering may be subject to specific legal or regulatory restrictions in certain jurisdictions. Bone Therapeutics SA and Bryan, Garnier & Co. take no responsibility for any violation of any such restrictions by any person. Any persons reading this announcement should inform themselves of and observe any such restrictions.

This announcement is not for release, publication or distribution, in whole or in part, directly or indirectly, in or into the United States (including its territories and dependencies, any State of the United States and the District of Columbia), Australia, Canada, Japan, South Africa or any jurisdiction into which the publication or distribution would be unlawful. This announcement is for information purposes only and does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire shares in the capital of Bone Therapeutics SA in the United States, Australia, Canada, Japan, South Africa or any jurisdiction in which such offer or solicitation would be unlawful or require preparation of any prospectus or other offer documentation or would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdictions. The shares that are to be sold in the Offering (the "Sale Shares") have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered, sold or transferred, directly or indirectly, within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and the securities laws of any state or other jurisdiction of the United States. No public offering of the Sale Shares referred to in this announcement is being made in the United States or elsewhere.

This announcement is not a prospectus within the meaning of Directive 2003/71/EC, as implemented in each member state of the European Economic Area, and amendments thereto, including Directive 2010/73/EU to the extent implemented in the relevant member State of the European Economic Area (together, the "Prospectus Directive") nor within the meaning of Regulation EU 2017/1129 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/CE (the "Prospectus Regulation").

This announcement does not, and shall not, in any circumstances, constitute a public offering, nor a public offer to sell or to subscribe for, nor a public solicitation to offer to purchase or to subscribe for, securities in any jurisdiction. No action has been taken by Bone Therapeutics SA or Bryan, Garnier & Co. or any of their respective affiliates to permit a public offering of the securities described in this announcement or possession or distribution of this announcement in any jurisdiction where action for that purpose is required.

With respect to the member states of the European Economic Area which have implemented the Prospectus Directive (each, a "Relevant Member State"), no action has been undertaken or will be undertaken to make an offer to the public of the shares of Bone Therapeutics SA requiring a publication of a prospectus in any Relevant Member State. As a consequence, the shares of Bone Therapeutics SA may only be offered or sold in any Relevant Member State pursuant to an exemption under the Prospectus Directive.

This announcement does not constitute a public offering of securities in the United Kingdom. In the United Kingdom, this document is directed only at Qualified Investors, being persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Financial Promotion Order"), (ii) "high net worth entities", "unincorporated associations" and to other persons to whom it may otherwise be lawfully communicated under Article 49(2)(a) to (d) of the Financial Promotion Order and (iii) to other persons to whom this announcement may be lawfully communicated (all such persons together being referred to as "relevant persons"). In the United Kingdom, any person who is not a relevant person should not act or rely on this announcement or any of its contents. In any EEA state other than the United Kingdom, this announcement should be relied upon only by Qualified Investors. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.

Bryan, Garnier & Co. Ltd. which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the UK, is acting exclusively for the Company and no one else in connection with the Offering. In connection with such matters, the Sole Bookrunner, its affiliates and its respective directors, officers, employees and agents will not regard any other person as its client, nor will they be responsible to any other person for providing the protections afforded to its clients or for providing advice in relation to the Offering or any other matters referred to in this announcement. Reported by GlobeNewswire 1 hour ago.
↧
↧

Gibson questions Australia's role as gatekeepers of the sledging 'line'

March 7, 2018, 7:20 am
$
0
0
"Whose line is it anyway," quizzes the South African coach in his defence of Quinton de Kock Reported by CricBuzz 1 hour ago.
↧

Siyata Mobile UR7 Rugged Clamshell Device Now Integrated With ESChat PTT

March 7, 2018, 7:17 am
$
0
0
MONTRÉAL, March 07, 2018 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (the "Company" or "Siyata") (TSX-V:SIM) (OTCQX:SYATF) is pleased to announce that it has passed integration and certification for its UR7 Rugged Clamshell Device (“*UR7*”) with ESChat, a leading US Push-to-Talk Over Cellular (“*PoC*”) software company. Josh Lober, President of ESChat, added, “We are excited to be working with Siyata, which is a fast-growing vendor of innovative PTT devices. ESChat delivers best-of-class PoC software, which coupled with Siyata’s UR7, provides enterprise customers a fantastic PTT experience.”

The integration opens opportunities for Siyata with ESChat's multiple cellular operator partners and end customers. 

Marc Seelenfreund, CEO and Chairman of Siyata Mobile, commented, “We are pleased to be working with ESChat, a leading North American PoC software vendor and are confident this will open up large-scale sales opportunities for our UR7 device. Our rugged clamshell, coupled with ESChat Push-to-Talk, is a perfect upgrade for outdated IDEN clamshell devices.”

The UR7 device is based on a Qualcomm Snapdragon chipset supporting major North American bands including 4G/LTE and FirstNet (“Band 14”) for the First Responders network. This device boasts 4G speed, crystal clear cellular call quality with background noise cancellation, dual speakers for loud and clear sound quality, dedicated Push-To-Talk (PTT) and SOS buttons, a touch screen and more, packaged in an ergonomic clamshell form factor.

CCS Insight predicts the market for rugged handsets will double from 30 million units in 2017, as more workers opt for durable phones that can withstand a harsh environment. CCS also expects the market to continue to expand rapidly, with volumes of over 59 million by 2021.

*About ESChat* 

ESChat (www.eschat.com) is the leading solution for carrier independent Secure Push to Talk (PTT) over LTE communications. ESChat includes AES-256 encrypted PTT voice and multimedia (text and image) messaging. ESChat also provides live and historical (bread crumb) tracking and mapping.  Currently used by the U.S. Military as well as federal, state and local law enforcement, ESChat is able to operate over and across any wireless network, including all commercial carriers, private 3G/4G networks and WiFi. ESChat supports interoperability with all LMR radio networks, including P25 via the native Inter RF Subsystem Interface (ISSI) protocol and DMR via the native Inter Application Interface Specification (AIS) protocol.

For more information please visit http://www.eschat.com/.

*Press Contact:
*For ESChat
Holly Luban
media@eschat.com

*About Siyata*

A TSX Venture Top 50 Company, Siyata Mobile Inc. is a leading global developer and provider of cellular communications systems for enterprise customers, specializing in connected vehicle products for professional fleets, marketed under the Uniden® Cellular brand. Since developing the world’s first 3G connected vehicle device, Siyata has been a pioneer in the industry, launching the world’s first 4G LTE all-in-one fleet communications device in 2017. Incorporating voice, push-to-talk over cellular, data, and fleet management solutions into a single device, the company aims to become the connected vehicle communications device of choice for commercial vehicles and fleets around the world.

Siyata also offers rugged phones for industrial users and signal boosters for homes, buildings, and fleets with poor cell coverage. Siyata’s customers include cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia, and the Middle East.

Visit www.siyatamobile.com and http://www.unidencellular.com/ to learn more.

On Behalf of the Board of Directors of:

*SIYATA MOBILE INC.*

Marc Seelenfreund
CEO and Chairman

*Investor Relations:*
Arlen Hansen
Kin Communications
1-866-684-6730
SIM@kincommunications.com

*Sales Department:*
Glenn Kennedy, VP Sales
Siyata Mobile Inc.
416-892-1823
glenn_kennedy@siyatamobile.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. Reported by GlobeNewswire 1 hour ago.
↧

Weiss Korea Opportunity Fund - Net Asset Value(s)

March 7, 2018, 7:31 am
$
0
0
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF IRELAND OR SOUTH AFRICA OR TO U.S. PERSONS Weiss Korea Opport... Reported by FinanzNachrichten.de 1 hour ago.
↧

Rio Tinto accelerates driverless fleet expansion in Australia

March 7, 2018, 8:12 am
$
0
0
Reported by SeekingAlpha 23 minutes ago.
↧
↧

BlackRock Frontiers Investment Trust Plc - Circular and Notice of General Meeting

March 7, 2018, 8:09 am
$
0
0
THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, FORWARDED TO OR TRANSMITTED, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC ... Reported by FinanzNachrichten.de 26 minutes ago.
↧

Stocks gain in Asia after China reports surge in exports

March 7, 2018, 9:58 pm
$
0
0
BANGKOK (AP) — Share prices rose in Asia on Thursday after China reported its exports surged nearly 45 percent in February from a year earlier. KEEPING SCORE: Japan's Nikkei 225 index edged 0.1 percent higher to 21,333.11 and Hong Kong's Hang Seng added 1.5 percent to 30,638.52. Australia's S&P ASX 200 surged 0.7 percent to 5,942.90 and the Kospi in South Korea gained 0.4 percent to 2,411.57. The Shanghai Composite index climbed 0.3 percent to 3,281.00 and shares were also higher in Southeast Asia. WALL STREET: Stocks fell in the morning as investors reacted to the departure of Gary Cohn, a former Goldman Sachs executive who was seen as a proponent of free trade. The losses deepened after Trump suggested on Twitter that the U.S. Reported by SeattlePI.com 11 hours ago.
↧
Search

Arnold to coach Australia after World Cup

March 7, 2018, 11:42 pm
$
0
0
Arnold to coach Australia after World Cup The 54-year-old will replace Bert van Marwijk following the Socceroos' World Cup campaign in Russia, starting in June Reported by Goal.com 9 hours ago.
↧

Nexcess Warns WordPress Hosting Clients Of Cryptojacking Threat

March 8, 2018, 12:05 am
$
0
0
Nexcess has warned WordPress hosting clients of the threat posed by cryptojacking attacks, which use compromised WordPress sites to mine cryptocurrencies such as Monero by hijacking the resources of visitors’ computers.

SOUTHFIELD, Mich. (PRWEB) March 08, 2018

Nexcess, a leading provider of performance-optimized managed WordPress hosting, has warned WordPress hosting clients of the threat posed by cryptojacking attacks, which use compromised WordPress sites to mine cryptocurrencies such as Monero by hijacking the resources of visitors’ computers.

Cryptojacking is a recent motivation for attacks against WordPress sites. Since the middle of last year it has become more common. The attackers inject malicious JavaScript code into compromised WordPress sites. The code, often the Coinhive mining script, runs in the browsers of site visitors, using their resources to mine cryptocurrencies. It has been estimated that 1,000 compromised WordPress sites could mine several thousand dollars’ worth of cryptocurrency each month, giving criminals a strong incentive to target WordPress sites.

“Cryptojacking is easy money for online criminals, so we expect to see an exponential increase in the number of attacks and in the sophistication of the malware this year,” commented Chris Wells, President and CEO of Nexcess. “WordPress hosting clients should be aware of the risk and the steps they need to take to avoid exposing site visitors to resource hijacking that generates revenue for organized crime.”

In recent months several variants of this attack have been seen. Last year, criminals began exploiting known vulnerabilities in out-of-date WordPress sites to inject cryptojacking malware. Earlier this year, a large botnet was used in brute force attacks against thousands of WordPress sites, injecting cryptojacking code on sites with poorly chosen passwords. Last month, popular accessibility plugin Browsealoud was compromised in a supply-chain attack against WordPress sites: the cryptomining malware was added to the plugin and distributed to WordPress sites when it was installed or updated.

To reduce the risk of a successful cryptojacking attack against their site, WordPress site owners should follow basic WordPress security protocols. Sites should be updated to install security patches. Two-factor authentication should be used to defend against brute-force attacks. WordPress users should be cautious when installing plugins and use malware scanning software to check for the presence of cryptomining code.

As a provider of WordPress hosting to thousands of publishers, bloggers, and eCommerce retailers across the US and Europe, Nexcess would like to raise awareness of the increasing prevalence of this type of attack against insecure WordPress sites and urge site owners to take the basic security precautions necessary to protect their sites and users.

About Nexcess

Nexcess is a Southfield, Michigan-based managed application hosting company founded in 2000, with data centers in the United States, Europe, and Australia. Nexcess offers application hosting services for Magento, WordPress, WooCommerce, Craft CMS, ExpressionEngine, and OroCRM, ranging from entry-level packages to custom clustered/complex hosting configurations, with an emphasis on achieving maximum performance for high-traffic sites. For more information, visit http://www.nexcess.net. Reported by PRWeb 9 hours ago.
↧
↧

Weather bureau staff investigated for alleged cryptocurrency mining on work computers

March 8, 2018, 1:25 am
$
0
0
Look, mining cryptocurrency off work computers mightn't be the greatest of ideas.

Two IT employees at Australia's Bureau of Meteorology are under investigation by the Australian Federal Police, alleged to have used the agency's computers to mine cryptocurrencies, according a report by ABC News.

SEE ALSO: Cryptocurrency ransom demands popped up in recent cyberattacks

Police executed a search warrant at the Melbourne headquarters of the organisation, questioning two employees while the rest of the IT staff were told to wait in a conference room. 

No charges have yet been laid, but one staffer is reportedly on leave. While it's not illegal to mine cryptocurrency per se, it could be considered an illegal use of government resources. Read more...

More about Australia, Bureau Of Meteorology, Cryptocurrency, Cryptocurrencies, and Cryptocurrency Mining Reported by Mashable 7 hours ago.
↧

SaferVPN review: Good features overshadowed by privacy concerns

March 8, 2018, 3:52 am
$
0
0
SaferVPN has been around since 2013 and is located in Israel—a country with stringent privacy laws that shield companies and citizens from its many forms of government surveillance. This, combined with the company’s no-logging policy, should keep any of your online doings safely under wraps while you’re using their services.

However, Israel has been known to share information with Five Eyes (FVEY), an intelligence sharing agreement between the U.S.A, U.K., Canada, New Zealand, and Australia. That the company maintains an office in New York City compounds concerns over this point. If you live in a Five, Nine, or Fourteen Eyes country and have concerns that regional laws may not be enough to keep your online activities from being shared with your government, SaferVPN’s services may not be for you.

To read this article in full, please click here Reported by Macworld 5 hours ago.
↧

Ramco Systems’ Aviation Suite goes live for Cobham Aviation Services

March 8, 2018, 5:05 am
$
0
0
Integrating with Financials and Analytics to bring real-time visibility

ADELAIDE, Australia / CHENNAI, India (PRWEB) March 08, 2018

Ramco Systems is pleased to announce the successful deployment of Ramco Systems’ Aviation Suite for Cobham Aviation Services. The Ramco Systems’ Aviation Suite provides an integrated and unified view of Cobham’s continued airworthiness, engineering, supply chain management and finance operations and the recent deployment marks the completion of the first phase of an engineering and finance transformation.

Cobham Aviation Services – which caters to clients in the defence, government and commercial sectors – began installing Ramco’s software as a part of an initiative to optimize business processes and reduce overheads for its global fleet of more than 130 aircraft around the world.

In Phase I of the implementation, beyond engineering, the scalable Aviation Suite also automates functions for compliance, maintenance costs and revenue tracking and financial reporting. It will improve supply chain efficiency and ensure continuous airworthiness of Cobham’s fixed and rotary-wing aircraft around the world. Phase II of the implementation will witness significant expansion of the scope of Cobham’s UK operations and productivity improvements with process refinements and automation in flight contracts, fixed assets and automation of supplier invoice processing through OCR (optical character recognition) integration.

Peter Brown, Vice President – Technical Services, Cobham Aviation Services, said, “Ramco’s aviation package has changed our processes for the better across our entire organisation. We are witnessing improvements in our fleet management and productivity thanks to Ramco’s user-friendly dashboard and mobility apps. We expect this technological transformation to translate into an improved bottom-line in the years ahead.”

Ramco offered a solution that is scalable and provides a high quality user experience; both these aspects were of fundamental importance to Cobham for it to drive usability and manage the change in an organisation that is diverse and dispersed.

Commenting on the go-live, Virender Aggarwal, CEO, Ramco Systems, said, “Cobham is a leading player in the aviation industry, and our team is delighted to have supported them in the go-live of this strategic transformation. This project has underscored our track record in specialised enterprise software, and we remain grateful to Cobham for trusting Ramco as their partner over the years.”    

Ramco Aviation Software is trusted by 21,000+ users to manage 4,000+ aircraft, globally. Designed to be accessible on cloud and mobile, Ramco Aviation Software continues to add technological innovations with ‘Anywhere Apps’, redefining the power of mobility, to significantly reduce transaction time both during aircraft-on-ground (AOG) conditions and critical aircraft turnarounds. Ramco is changing the paradigm of enterprise software with ZERO UI powered by cool new features such as Chatbots, Mail bots, HUBs and Cognitive solutions. Furthering this, the company has also developed application compatibility on Microsoft HoloLens to bring Augmented Reality which improves efficiency in maintenance operations. With 75+ Aviation leaders onboard, Ramco is the solution of choice for several large airlines and top heli-operators and multiple MROs in the world.

About Cobham Aviation Services:
We deliver outsourced aviation services for military and civil customers worldwide through training, special mission flight operations, outsourced commercial aviation and aircraft engineering. For more information, visit cobhamaviationservices.com

About Ramco Systems:
Ramco is a fast-growing enterprise software player disrupting the market with its multi-tenant cloud and mobile-based enterprise software in the area of HCM and Global Payroll, ERP and M&E MRO for Aviation. Part of the USD 1 billion Ramco Group, Ramco Systems focuses on Innovation and Culture to differentiate itself in the marketplace. On Innovation front, Ramco has been focusing on moving towards Cognitive and Robotic ERP with features such as Bot It – which allows users to complete transaction using natural conversations; Mail it – transact with the application by just sending an email; HUB It - a one screen does it all concept built to address all activities of a user; Thumb It – mobility where the system presents users with option to choose rather than type values and Prompt It – a cognitive ability which will let the system complete the transaction and prompts the user for approval.

With 1,600+ employees spread across 24 offices globally, Ramco follows a flat and open culture where employees are encouraged to share knowledge and grow. No Hierarchies, Cabin-less Offices, Respect work and not titles, among others are what makes the team say, ‘Thank God it’s Monday!’

Winner of Brandon Hall Group Excellence in Technology Awards 2017, for Best Advance in Time and Labor Management;
Winner of the HR Vendors of the Year 2017 Awards for Best Payroll Software, Best HR Management System and Best Talent Management Software;
Only APAC vendor to be positioned in Gartner Magic Quadrant for Cloud Financials & Cloud HCM Suites;
Enters as a Contender in The Forrester Wave™: SaaS Human Resource Management Systems, Q3 2017; Recognized as a ‘Highly Recommended’ Payroll Software Supplier of the Year 2017 by Global Payroll Association; Positioned as ‘Achiever’ in Everest Group's Multi-Country Payroll Platform Assessment

For more information, please visit http://www.ramco.com/aviation
Follow Ramco on Twitter @ramcosystems / @ramcoaviation and stay tuned to http://blogs.ramco.com

For further information, contact:
Vinitha Ramani
Global Head of Brand and Communications at Ramco Systems
+91 44 6653 4204
vinitharamani@ramco.com Reported by PRWeb 4 hours ago.
↧
Viewing all 53225 articles
Browse latest View live
More Pages to Explore .....
Search

Latest Images

Eco Data 4/26/24

Eco Data 4/26/24

April 25, 2024, 5:00 pm
‘Pay day every day’ may become Shangri-La Group, BPOs’ secret to happy employees

‘Pay day every day’ may become Shangri-La Group, BPOs’ secret to happy employees

April 25, 2024, 5:51 am
Nonprofit donates custom home in this East Bay city for Marine injured in...

Nonprofit donates custom home in this East Bay city for Marine injured in...

April 23, 2024, 7:00 am
New private rooms on Tokaido Shinkansen change the way we travel from Tokyo...

New private rooms on Tokaido Shinkansen change the way we travel from Tokyo...

April 22, 2024, 6:00 am
Ukraine bans military from online gambling amid addiction concerns

Ukraine bans military from online gambling amid addiction concerns

April 22, 2024, 5:17 am
ಮಂಡ್ಯದಿಂದ ಸುಮಲತಾ ದೂರ; ಹೆಚ್‌ಡಿಕೆ ಪರ ಪ್ರಚಾರಕ್ಕಿಳಿಯದ ಸಂಸದೆ –ಬರ್ತಾರೆ ನೋಡೋಣ ಎಂದ...

ಮಂಡ್ಯದಿಂದ ಸುಮಲತಾ ದೂರ; ಹೆಚ್‌ಡಿಕೆ ಪರ ಪ್ರಚಾರಕ್ಕಿಳಿಯದ ಸಂಸದೆ –ಬರ್ತಾರೆ ನೋಡೋಣ ಎಂದ...

April 20, 2024, 8:08 pm
OCBC Bank Singapore Offers Up to 2.8% p.a. Fixed Deposit Promotion from 21...

OCBC Bank Singapore Offers Up to 2.8% p.a. Fixed Deposit Promotion from 21...

April 20, 2024, 12:38 pm
National Poetry Month 2024: Maxine Starr

National Poetry Month 2024: Maxine Starr

April 19, 2024, 9:56 am
Vegan Chicken Pot Pie

Vegan Chicken Pot Pie

April 19, 2024, 9:18 am
Firefox UX: On Purpose: Collectively Defining Our Team’s Mission Statement

Firefox UX: On Purpose: Collectively Defining Our Team’s Mission Statement

April 19, 2024, 7:03 am